Prior Authorization: How Insurers Gatekeep GLP-1 Coverage
Prior authorization is the main tool insurers use to manage GLP-1 drug costs. Here's how the process typically works and what commonly triggers a denial.
By the GLP Semaglutide editorial team · Last updated January 5, 2026
Prior authorization requires a prescriber to submit clinical documentation to an insurer justifying a prescription before the plan will cover it — a standard utilization management tool that insurers apply heavily to high-cost GLP-1 drugs, particularly for weight-management indications.
Common documentation requirements
Plans commonly require documentation of BMI thresholds, specific comorbidities, prior attempts at other weight-management approaches, or an on-label diagnosis (like type 2 diabetes) before approving coverage — criteria that vary meaningfully by plan.
If you're denied
Insurers are generally required to provide an appeals process for denied prior authorizations. Your plan's denial letter should outline the specific reason and the appeal process — a prescriber's office can often help navigate resubmission with additional documentation.
Primary sources